Rezolute Bio
  • Investors & Media
    • Overview
    • Corporate Presentation
    • News
    • Events
    • Stock Quote and Chart
      • Historical Data
    • Analyst Coverage
    • SEC Filings
    • Governance
    • Info
  • Contact Us
  • Therapeutic Focus
    • Pipeline
    • RZ358
    • RZ402
    • Publications
    • Data Presentations
  • For Patients
    • Overview
    • Living with HI
    • Living with DME
  • About
    • Our Mission
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
  • Join Us
    • Our Mission
    • Open Positions
    • Benefits
  • Contact Us
  • Investors & Media
    • Overview
    • Corporate Presentation
    • News
    • Events
    • Stock Quote and Chart
      • Historical Data
    • Analyst Coverage
    • SEC Filings
    • Governance
    • Info

Press Releases

  • News & Events

  • Overview
  • IR Calendar
May 01, 2017 8:00am EDT

AntriaBio Formally Engages CRO for the Conduct of its Phase I First-in-Human Clinical Trial of AB101

Mar 22, 2017 8:00am EDT

AntriaBio Appoints Two Pharmaceutical Executives to its Board of Directors

Dec 15, 2016 5:15pm EST

AntriaBio Announces Offer to Amend Warrants to Purchase Shares of Common Stock

Sep 22, 2016 8:00am EDT

AntriaBio Announces Formation of Subsidiary and Plan to Raise Capital in South Korea

Jun 29, 2016 8:00am EDT

AntriaBio Announces $12 Million Private Placement

Jun 22, 2016 8:00am EDT

AntriaBio Announces Preclinical Proof of Concept for Once-Weekly Basal Insulin AB101 in Diabetic Miniature Swine

Jan 06, 2016 8:30am EST

AntriaBio Announces Appointment of Michael Deperro as Vice President of Operations

Dec 10, 2015 12:50pm EST

AntriaBio Announces First Close of Private Placement Transaction

Nov 17, 2015 8:30am EST

AntriaBio Receives Notice of Allowance on Patent Covering Microsphere Drug Delivery Platform

Sep 16, 2015 7:30am EDT

AntriaBio Announces New Product Candidate, AB301, a Weekly GLP-1 Agonist and Basal Insulin Combination, for Type 2 Diabetes

  • arrow_back
  • 1…
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • arrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
rezolute logo

©2023 Rezolute, Inc.

Explore

  • Therapeutic Focus
  • For Patients
  • About
  • Join Us
  • Contact Us
  • Investors & Media

Contact

Corporate Headquarters

275 Shoreline Drive
Suite 500
Redwood City, CA 94065
+1 (650) 206-4507
info@rezolutebio.com

Investor Relations

Investor Relations Contacts

Legal

  • Terms of Use
  • Privacy Policy
MENU
  • Therapeutic Focus
    • Pipeline
    • RZ358
    • RZ402
    • Publications
    • Data Presentations
  • For Patients
    • Overview
    • Living with HI
    • Living with DME
  • About
    • Our Mission
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
  • Join Us
    • Our Mission
    • Open Positions
    • Benefits
  • Contact Us
  • Investors & Media
    • Overview
    • Corporate Presentation
    • News & Events
    • Stock Quote and Chart
      • Historical Data
    • Analyst Coverage
    • SEC Filings
    • Governance
    • Info